| HOME >> BIOLOGY >> TECHNOLOGY |
NOVATO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 28, at 5:00 p.m. ET to discuss third quarter 2009 financial results.
U.S. / Canada Dial-in Number: 800.299.6183
International Dial-in Number: 617.801.9713
Participant Code: 51404008
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 51416825
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.
Contacts:
Investors Media
Eugenia Shen Susan Berg
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 506-6570 (415) 506-6594
SOURCE BioMarin Pharmaceutical Inc.
'/>"/>
| SOURCE BioMarin Pharmaceutical Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. BioMarin to Present at the Morgan Stanley Healthcare Conference
2. BioMarin to Present at the Baird Healthcare Conference
3. BioMarin to Present at the Jefferies Healthcare Conference
4. BioMarin to Present at the Goldman Sachs Healthcare Conference
5. BioMarin to Present at the Deutsche Bank Health Care Conference
6. BioMarin to Present at the Baird Growth Stock Conference
7. BioMarin Announces First Quarter 2009 Financial Results
8. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
9. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
10. BioMarin to Present at the 4th Annual Citi Biotech Day
11. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |